In clinical practice, lorlatinib (targets: ALK/ROS1) is associated with primarily mild to moderate side effects, including hypercholesterolemia (82.4%), hypertriglyceridemia (60.7%), edema (51.2%), peripheral neuropathy (43.7%), and central nervous system effects (39.7%),26 but edema has also been reported with alectinib (targets: ALK/RTK),27 suggesting that specific inhibition of ROS1 but not ALK may reduce edema. The gene discussed is ROS1; the disease is hypertriglyceridemia.